Novo Nordisk's flagship product is semaglutide. Sold under the names Ozempic and Wegovy, it's one of the leading GLP-1 ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

US stocks were mixed Thursday as President Trump's sweeping tariffs hit dozens of US trade partners after his self-imposed ...

Eli Lilly’s experimental oral GLP-1 medication, orforglipron, led to an average weight loss of 12.4%, or 27.3 pounds, in a phase 3 trial involving more than 3,000 adults.  Based on the results, the ...

AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a ...

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a ...

Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...

Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...